수산양식용 백신 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Aquaculture Vaccines Market was valued at USD 407.4 million in 2024 and is projected to grow at a CAGR of 8% from 2025 to 2034. This growth is fueled by increasing seafood demand worldwide and the push for sustainable aquaculture practices.

The expansion of fish farming to meet dietary needs has highlighted challenges like disease outbreaks, which can significantly impact profitability and productivity. Vaccination has become an essential tool to prevent infections, reduce dependency on antibiotics, and minimize losses. Governments and regulatory bodies are actively promoting vaccination programs to enhance fish health and welfare, driving market growth further. Technological advancements in vaccine development, such as recombinant DNA and subunit vaccines, are improving vaccine efficacy and safety, supporting market expansion. Additionally, growing investments in aquaculture infrastructure in developing regions are creating new opportunities for vaccine manufacturers.

Aquaculture vaccines are biological formulations used to prevent and manage diseases in farmed aquatic species. These vaccines promote animal health, enhance production efficiency, and support sustainable practices by reducing antibiotic use.

The market is segmented by vaccine type into inactivated, live attenuated, subunit, and others. In 2024, inactivated vaccines held the largest market share, valued at USD 302.6 million. These vaccines are highly preferred for their safety, long-lasting immunity, and cost-effectiveness. Their ability to protect fish populations without environmental risks has made them a critical component of aquaculture disease management.

By route of administration, the market includes injection, immersion, spray, and oral vaccines. Injection vaccines led the market in 2024, accounting for 60.8% of the share. Their effectiveness in directly delivering antigens to stimulate immune responses makes them a popular choice for controlling bacterial and viral diseases in aquaculture.

Based on application, the bacterial vaccine segment dominated in 2024 and is expected to reach USD 430.4 million by 2034. This growth is driven by the increasing prevalence of bacterial infections in farmed aquatic species and the development of advanced vaccines offering enhanced protection.

The salmon segment is projected to grow at a CAGR of 8.1%, driven by its commercial importance and vulnerability to diseases. Rising demand for fish protein and sustainable practices are further supporting vaccine adoption.

Europe leads the aquaculture vaccines market, with significant contributions from countries with strong aquaculture industries. The region's focus on fish health and welfare continues to drive demand for vaccines.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Surging prevalence of bacterial and viral infections
    • 3.2.1.2 Increasing aquaculture production across the globe
    • 3.2.1.3 Development and launch of new aquaculture vaccines
    • 3.2.1.4 Rising adoption of aquaculture vaccines over antibiotics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory policies for vaccine approval
    • 3.2.2.2 Complex vaccine development procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Inactivated vaccine
• 5.3 Live attenuated vaccine
• 5.4 Subunit vaccine
• 5.5 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Injection vaccines
• 6.3 Immersion and spray
• 6.4 Oral vaccines

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Bacterial
• 7.3 Viral
• 7.4 Parasitic
• 7.5 Combined

Chapter 8 Market Estimates and Forecast, By Species, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Salmon
• 8.3 Trout
• 8.4 Tilapia
• 8.5 Seabass
• 8.6 Seabream
• 8.7 Turbot
• 8.8 Carp
• 8.9 Other species

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Norway
  • 9.3.7 Ireland
  • 9.3.8 Turkey
  • 9.3.9 Denmark
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Indonesia
  • 9.4.4 Philippines
  • 9.4.5 Thailand
  • 9.4.6 Vietnam
  • 9.4.7 Australia
  • 9.4.8 New Zealand
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Chile
• 9.6 Middle East and Africa
  • 9.6.1 Iran
  • 9.6.2 Egypt

Chapter 10 Company Profiles

• 10.1 CIBA
• 10.2 HIPRA
• 10.3 Kyoto Biken Laboratories
• 10.4 Kemin Industries
• 10.5 Kyoritsuseiyaku Corporation
• 10.6 Merck Animal Health (Merck & Co.)
• 10.7 Nisseiken
• 10.8 Phibro Animal Health Corporation
• 10.9 Tecnovax
• 10.10 Virbac
• 10.11 Veterquimica
• 10.12 Vaxxinova International
• 10.13 Zoetis